thromboembolic

Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.

AZD1283 is an effective P2Y12 receptor antagonist (EC50: 3.0 ug/kg/min, binding IC50: 11 nM). AZD1283 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg/kg/min, respectively. The doses induced the increase in bleeding time at 33 and 100 μg/kg/min for 3- and 13-fold, respectively. Thus, the therapeutic index (TI) was ≥10 for both compounds.

EMD-503982 is a potential Factor Xa and Factor VIIa inhibitor with potential anticancer and antitumor activity for the study of thromboembolic and neurological disorders.

Abelacimab (MAA868), a fully human IgG1 monoclonal antibody that binds to and blocks the activation of FXI, is an anticoagulant used in the study of thromboembolic diseases.

Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is able to be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with K i s of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and is potential for thromboembolic diseases treatment [1] [2] [3].

Cyproheptadine hydrochloride is an effective orally active 5-HT2A receptor antagonist with antidepressant, anti-serotonin, and antiplatelet activities. It can be used for research on thromboembolic diseases and for the establishment of diabetes models.

DS-1040 Tosylate is a thrombin-activated fibrinolysis inhibitor (TAFIa) inhibitor, also a fibrinolysis enhancer, inhibiting TAFIa and carboxypeptidase N, reducing fibrin clots in the lungs, useful in thromboembolic disease research.

S-18326 is a potent and selective thrombin inhibitor, specifically designed for the treatment of thromboembolic disorders.

FXIIa-IN-3 (Compound 8) is an effective and selective inhibitor of Factor XIIa (FXIIa), with an IC50 of 0.045 μM. It demonstrates significant selectivity over related serine proteases, including FXIa, FXa, and FIXa. FXIIa-IN-3 is suitable for research in thromboembolic diseases.

Jujuboside B has potent inhibitory effects on collagen-, thrombin-, AA-, and ADP-induced aggregation, and also exhibits superior protection on the thromboembolic model.

Cyproheptadine is an effective orally active 5-HT2A receptor antagonist with antidepressant, anti-serotonin, antiplatelet, and antithrombotic properties. It can be used for research on thromboembolic diseases and for the development of diabetes models.

FXa-IN-1 is an FXa inhibitor with an IC50 value of 3 nM and a Ki value of 0.7 nM that exhibits good oral bioavailability and half-life (in vivo) and can be used to study thromboembolic diseases.

FXIa-IN-9 (compound 3f) is a potent, selective inhibitor of FXIa, demonstrating strong binding affinity through hydrogen bond formation (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). It exhibits anticoagulant properties, making it valuable for research into thromboembolic conditions, including atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism [1].

Edoxaban (DU-176b) hydrochloride is a potent, selective, orally active, direct inhibitor of Factor Xa (FXa), targeting human free FXa (Ki: 0.561 nM) and thrombinogenase (Ki: 2.98 nM). Over 10,000 times more selective than other thrombinases, it is suitable for studies to prevent thromboembolic disease.

YM-60828 dihydrochloride is a Factor Xa (FXa) inhibitor and anticoagulant used in the treatment of venous thromboembolic disease.

Efegatran, also known as GYKI-14166, RGH-2958 and LY294468, a thrombin inhibitor which is being developed by IVAX for the potential treatment of thromboembolic disorders.

GCC-4401C methanesulfonate is a factor Xa inhibitor similar to rivaroxaban that is currently under development for venous thromboembolic disease (VTE).

GCC-4401C free base is a factor Xa inhibitor similar to rivaroxaban that is currently under development for venous thromboembolic disease (VTE).

Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an inhibitory effect on thrombin generation, has an anticoagulant effect, and is used in the study of thromboembolic diseases. Thromboembolic Diseases